 | |
| Clinical data | |
|---|---|
| Trade names | Lopid, Jezil, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a686002 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Fibrates[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Close to 100% |
| Protein binding | 95% |
| Metabolism | Hepatic (CYP3A4) |
| Elimination half-life | 1.5 hours |
| Excretion | Renal 94% Feces 6% |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C15H22O3 |
| Molar mass | 250.338 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 61 to 63 °C (142 to 145 °F) |
| |
| |
| (verify) | |
Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels.[1] Its is generally less preferred than statins.[1][3] Use is recommended together with dietary changes and exercise.[1] It is unclear if it changes the risk of heart disease.[1] It is taken by mouth.[1]
Common side effects include headache, dizziness, feeling tired, and intestinal upset.[1] Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown.[1] Use in pregnancy and breastfeeding is of unclear safety.[4] It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.[1]
Gemfibrozil was patented in 1968 and came into medical use in 1982.[5] It is available as a generic medication.[3] A month supply in the United Kingdom costs the NHS about 30 £ as of 2019.[3] In the United States the wholesale cost of this amount is about 6 USD.[6] In 2017, it was the 138th most commonly prescribed medication in the United States, with more than four million prescriptions.[7][8]
References edit
- ^ a b c d e f g h i j k "Gemfibrozil Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 5 September 2020.
- ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 198–199. ISBN 9780857113382.
- ^ "Gemfibrozil Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.
- ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Gemfibrozil - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.